FindTrial
Sign In

Endocrine Therapy 1

DRUG2 trials

Sponsors

Pfizer, Sun Yat-sen University

Conditions

Advanced/Metastatic Breast CancerHER2-Positive Metastatic Breast CancerHR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

Phase 1

A Study of PF-06873600 in People With Cancer
TerminatedNCT03519178
PfizerHR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Start: 2018-03-07End: 2024-10-30Updated: 2025-11-14

Phase 2

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
RecruitingNCT07610720
Sun Yat-sen UniversityAdvanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer
Start: 2026-06-01End: 2029-11-01Target: 57Updated: 2026-05-28

Related Papers

Abstract P5-16-06: A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer
Cancer Research2022-02-1510 citations